

# Michiel S Van Der Heijden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4505978/publications.pdf>

Version: 2024-02-01

35  
papers

11,851  
citations

361413  
20  
h-index

395702  
33  
g-index

36  
all docs

36  
docs citations

36  
times ranked

13386  
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF $\beta$ 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	27.8	3,359
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	13.7	3,077
3	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 67-76.	13.7	1,728
4	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 748-757.	13.7	1,142
5	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	1.9	638
6	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	30.7	407
7	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. <i>Nature Medicine</i> , 2020, 26, 1839-1844.	30.7	245
8	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	10.7	225
9	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. <i>European Urology</i> , 2016, 69, 384-388.	1.9	177
10	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
11	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. <i>European Urology</i> , 2019, 75, 435-444.	1.9	97
12	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5082-5093.	7.0	82
13	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <i>Scientific Reports</i> , 2017, 7, 5554.	3.3	73
14	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
15	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. <i>European Urology</i> , 2021, 80, 7-11.	1.9	60
16	A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. <i>European Urology</i> , 2017, 71, 858-862.	1.9	59
17	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	1.9	56
18	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019, 11, 60.	8.2	36

#	ARTICLE	IF	CITATIONS
19	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2013, 13, 561.	2.6	27
20	Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 351-360.	0.4	24
21	Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram. <i>European Urology Focus</i> , 2019, 5, 718-721.	3.1	19
22	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	5.4	18
23	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793964.	4.8	13
24	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 342.e7-342.e14.	1.6	11
25	Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage <sc>III</sc>) urothelial cancer. <i>International Journal of Cancer</i> , 2022, 151, 2004-2011.	5.1	11
26	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100266.	1.7	10
27	Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 10952.	3.3	9
28	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. <i>Scientific Reports</i> , 2021, 11, 13683.	3.3	8
29	Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2015.01.014">http://dx.doi.org/10.1016/j.eururo.2015.01.014</a> . <i>European Urology</i> , 2015, 68, e33-e34.	1.9	6
30	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. <i>European Urology Focus</i> , 2022, 8, 995-1002.	3.1	6
31	The Molecular Background of Urothelial Cancer: Ready for Action?. <i>European Urology</i> , 2015, 67, 202-203.	1.9	5
32	Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019, 201, 478-485.	0.4	4
33	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	12.8	3
34	A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e173-e179.	1.9	1
35	Reply to Alessia Cinadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , 2021, 79, e20-e21.	1.9	0